N@N

GENVEC INC (NASDAQ:GNVC), Down By 10.35% ($0.04) From $0.425 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2011-03-14 08:11:00 - WOPRAI}
 

March 14, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, March 9th 2011 stating that GENVEC INC (NASDAQ:GNVC) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=gnvc&id=152396

At the time this story was written, GENVEC INC (NASDAQ:GNVC) is Down By 10.35% ($0.04) From $0.425 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

GENVEC INC (NASDAQ:GNVC) - GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III clinical trial for the treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic for the treatment of various cancers, including esophageal cancer, head and neck cancer, rectal cancer, and soft tissue sarcomas. In addition, its hearing and balance disorders program investigates delivery of the atonal gene in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and herpes simplex virus type 2. The company has a research collaboration and licensing agreement with Novartis Institutes for BioMedical Research, Inc. to discover and develop treatments for hearing loss and balance disorders. It also has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATHS malaria vaccine initiative, the U.S. Naval Medical Research Center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. GENVEC INC (NASDAQ:GNVC) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net